Therapeutic Asset Ratings

462 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
sar445877 Neoplasm	Sanofi	P1/2	CC (40)
sb-4826 Neoplasm	University of California, San Diego	P1/2	CC (40)
Shr-7367 Neoplasm	Shanghai Hengrui Pharmaceutical Co., Ltd.	P1/2	CC (40)
Shr-9839 Solid Tumor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P1/2	CC (40)
Shr-9839 For Neoplasm	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P1/2	CC (40)
smp3124lp Neoplasm	Sumitomo Pharma America, Inc.	P1/2	CC (40)
Stc-15 Neoplasm	STORM Therapeutics LTD	P1/2	CC (40)
t3011 Neoplasm	ImmVira Pharma Co. Ltd	P1/2	CC (40)
Ter-2013 Neoplasm	Terremoto Biosciences Inc.	P1/2	CC (40)
Test Product Hy0001A For Neoplasm	Sichuan Huiyu Pharmaceutical Co., Ltd	P1/2	CC (40)
Test Product Hyp-6589 Neoplasm	Sichuan Huiyu Pharmaceutical Co., Ltd	P1/2	CC (40)
th9619 Neoplasm	One-carbon Therapeutics AB	P1/2	CC (40)
TIPIRACIL Neoplasm	Parabilis Medicines, Inc.	P1/2	CC (40)
tng456 Neoplasm	Tango Therapeutics, Inc.	P1/2	CC (40)
Trifluridine Neoplasm	Parabilis Medicines, Inc.	P1/2	CC (40)
tu2218 Neoplasm	TiumBio Co., Ltd.	P1/2	CC (40)
Tyra-300 Neoplasm	Tyra Biosciences, Inc	P1/2	CC (40)
Vert-002 Neoplasm	Pierre Fabre Medicament	P1/2	CC (40)
Vodudeutentan sodium Neoplasm	ENB Therapeutics, Inc	P1/2	CC (40)
Vorbipiprant Neoplasm	Rottapharm Biotech	P1/2	CC (40)
Vsv-Ifnβ-Nis Neoplasm	Vyriad, Inc.	P1/2	CC (40)
XS-02 Neoplasm	NovaOnco Therapeutics Co., Ltd.	P1/2	CC (40)
yh42946 Neoplasm	Yuhan Corporation	P1/2	CC (40)
zg005 Neoplasm	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P1/2	CC (40)
zg006 Neoplasm	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P1/2	CC (40)

Showing 201 to 225 of 462 assets